Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05211570 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

StatusRecruiting
PhasePhase 1/2
SponsorAB Science
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated October 2, 2025 (before its estimated August 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Dec 2024 to Aug 2026 Completion date: Dec 2024 to Dec 2026 · Interventions: AB8939 (Drug), Azacitidine (Drug) to AB8939 (Drug), Venetoclax (Drug)v7 Show 2 more changesShow less
    • Completion date: Dec 2024 to Dec 2026
    • Interventions: AB8939 (Drug), Azacitidine (Drug) to AB8939 (Drug), Venetoclax (Drug)
  2. Primary and study completion dates: Jun 30, 2023 to Dec 2024v6
  3. Study sites: 5 to 10v5
  4. Trial status: Not Yet Recruiting to Recruiting Study sites: 2 to 5v4 Show 1 more changeShow less
    • Study sites: 2 to 5
  5. Start date: Mar 1, 2022 to Jun 1, 2022 Study sites: 1 to 2v3 Show 1 more changeShow less
    • Study sites: 1 to 2
  6. Re-verified, no change to tracked fieldsv2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The primary objective is to define the safety and tolerability of AB8939 in patients with AML by determining the dose-limiting toxicities, the maximum tolerated dose, and the recommended dose for dose expansion study.
Trial Details
NCT Number NCT05211570
Lead Sponsor AB Science
Conditions Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse, Myelodysplastic Syndrome Acute Myeloid Leukemia
Enrollment 78 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov